Bay State Times
SEE OTHER BRANDS

The latest news from Massachusetts

Bay State Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.

Press releases published on May 6, 2025

IPG Photonics Announces First Quarter 2025 Financial Results

IPG Photonics Announces First Quarter 2025 Financial Results

Growth from Strategic Initiatives Drove Revenue Above the Midpoint of Guidance Book-to-Bill was Above One and Highest in Over Two Years MARLBOROUGH, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP) today reported financial …

Coralogix Launches Advanced Continuous Profiling to Accelerate Issue Resolution Without Slowing Production

Coralogix Launches Advanced Continuous Profiling to Accelerate Issue Resolution Without Slowing Production

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Coralogix, the first cross-stack observability platform provider, today announced Continuous Profiling, an advanced capability that delivers unparalleled real-time visibility into application performance without any …

Liberty Defense Completes Third Party Testing with National Safe Skies Alliance for Aviation Security

Liberty Defense Completes Third Party Testing with National Safe Skies Alliance for Aviation Security

WILMINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE: E30), a leading technology provider of Artificial Intelligence (AI) based next generation detection solutions to …

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results …

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it …

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, …

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European …

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen …

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service